ClinicalTrials.gg
TerminatedNCT02923531Updated Dec 29, 2022Results posted

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

A Phase 1/2 interventional study of X4P-001 and Nivolumab in Clear Cell Renal Cell Carcinoma, sponsored by X4 Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-29.

Sponsored by X4 Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Due to low enrollment, the study was terminated early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 156 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
877th of 1,008
9 · median 40
Started
2016
with 42 others
Phase 1/2
146 of 1,142
31 open now
Registered
644th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 877th largest by enrollment of the 1,008 interventional ones that give a count, is one of 43 that started in 2016, is one of 146 in phase 1/2, and was the 644th registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

156 of the 1,142 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the combination of X4P-001 plus nivolumab is safe and tolerable. Secondly, the study will investigate if adding X4P-001 to nivolumab treatment has an effect on the body and the cancer tumor, in participants receiving nivolumab but not exhibiting a radiological response.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of Renal Cell Carcinoma with a documented clear cell component (ccRCC).
  • Currently receiving nivolumab and considered by Investigator to have the potential to derive clinical benefit from continuing treatment with nivolumab.
  • Based on (RECIST) Version 1.1 criteria on current nivolumab treatment (prior to initiation of this study), has a best response of confirmed stable disease (SD) or confirmed progressive disease (PD). Confirmed SD or confirmed PD refers to a response that is confirmed by a second scan which is at least 4 weeks apart from the previous scan.
  • At least one extra-renal measurable target lesion meeting the criteria of RECIST Version 1.1.
  • Agree to use from screening, through the study, and for at least 5 months after the last dose of nivolumab as follows: for women of agree to use highly-effective contraceptive methods; for males, agree to use a condom with sexual partner.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing.
  • of less than 3 months.
  • Performance status greater than or equal to (≥) 2 ( [ECOG] criteria).
  • (NYHA) Class III or IV, uncontrolled hypertension, or arrhythmia.
  • Previously received X4P-001.
  • Has a second . Except: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type.
  • Has active central nervous system (CNS) (including evidence of cerebral edema by Magnetic Resonance Imaging [MRI], or progression from prior imaging study, or any requirement for , or clinical symptoms of/from ) within 28 days prior to study treatment. Subjects with known CNS metastases must have a baseline MRI scan within 28 days of study treatment.
  • Ongoing clinical adverse events National Cancer Institute (NCI CTCAE) Grade greater than (>) 2 resulting from prior cancer therapies.
  • Known history of (HIV) or Acquired Immunodeficiency Syndrome (AIDS); or positive test for virus (HCV), or surface antigen (HBsAg).
  • History of clinically significant or uncontrolled cardiac, hepatic, or pulmonary disease.
  • Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Class B or C), or organ transplantation.
  • Inadequate hematologic, hepatic, or renal function.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    X4P-001 Plus Nivolumab

    Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study medication will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.

    Drug: X4P-001 · Drug: Nivolumab

Interventions

  • X4P-001 will be administered as per the dose and schedule specified in the arm.

  • Nivolumab will be administered as per the dose and schedule specified in the arm.

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Drug-related TEAEs: TEAEs with possible, probable, definite, or missing relationship to study medication (X4P-001 or Nivolumab). Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as events occurring on or after the first dose of study drug through 30 days after the last dose. Any TEAEs included both serious and non-serious TEAEs. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in Reported AE section.

    Time frame: From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of X4P-001

    Samples were to be analyzed for X4P-001 concentration using reversed-phase high performance liquid chromatography (RP-HPLC) with tandem mass spectrometry (MS) detection.

    Time frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of X4P-001

    Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

    Time frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

  3. Minimum Plasma Concentration (Cmin) of X4P-001

    Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

    Time frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

  4. Time to Reach Cmax (Tmax) of X4P-001

    Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

    Time frame: Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

  5. Objective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)

  6. Duration of Objective Response (DOR), Evaluated Using RECIST Version 1.1

    DOR was defined as the time from first CR or PR whichever comes first until the time of disease progression by RECIST v1.1 or death due to any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

    Time frame: Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)

  7. Time to Objective Response, Evaluated Using RECIST Version 1.1

    Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever comes first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)

  8. Disease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.1

    Disease control rate was defined as percentage of participants with best overall response of CR or PR or SD. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)

  9. Progression Free Survival (PFS), Evaluated Using RECIST Version 1.1

    PFS was defined as the time from first administration of study medication until objective tumor progression or death from any cause. Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)

  10. Time to Progression (TTP), Evaluated Using RECIST Version 1.1

    TTP was defined as the time from first administration of study medication until objective tumor progression. Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

    Time frame: From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)

07

Results

Posted Dec 29, 2022
Limitations and caveats
Due to low enrollment, the study was terminated early. Data for some pre-registered endpoints were therefore not collected or analysed and could not be reported.

Participant flow

Participant flow — Overall Study
MilestoneX4P-001 Plus Nivolumab
Started9
Received at least 1 dose of study medication9
Completed0
Not completed9
Withdrew: Adverse event4
Withdrew: Clinical deterioration1
Withdrew: Disease progression3
Withdrew: Study termination1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Drug-related TEAEs: TEAEs with possible, probable, definite, or missing relationship to study medication (X4P-001 or Nivolumab). Serious AEs: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as events occurring on or after the first dose of study drug through 30 days after the last dose. Any TEAEs included both serious and non-serious TEAEs. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in Reported AE section.

Time frame:
From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsX4P-001 Plus Nivolumab
Any TEAEs9
Serious TEAEs2
X4P-001-Related TEAEs9
Nivolumab-Related TEAEs9
SecondaryMaximum Observed Plasma Concentration (Cmax) of X4P-001

Samples were to be analyzed for X4P-001 concentration using reversed-phase high performance liquid chromatography (RP-HPLC) with tandem mass spectrometry (MS) detection.

Time frame:
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

No measurements were reported for this outcome.

SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC) of X4P-001

Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

Time frame:
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

No measurements were reported for this outcome.

SecondaryMinimum Plasma Concentration (Cmin) of X4P-001

Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

Time frame:
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

No measurements were reported for this outcome.

SecondaryTime to Reach Cmax (Tmax) of X4P-001

Samples were to be analyzed for X4P-001 concentration using RP-HPLC with tandem MS detection.

Time frame:
Predose (-30 minutes) on Day 1 of Cycle 1; predose (-10 minutes) on Days 8, 15, and 22 of Cycle 1, and Day 1 of Cycle 3; postdose at 60 and 90 minutes, and 2, 3 4, and 8 hours on Day 22 of Cycle 1

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

ORR was defined as percentage of participants with best overall response of complete response (CR) or partial response (PR). CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to less than (\<) 10 millimeters (mm). PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsX4P-001 Plus Nivolumab
Objective Response Rate (ORR): Percentage of Participants With Objective Response, Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.111.1 (0.3 to 48.2)
SecondaryDuration of Objective Response (DOR), Evaluated Using RECIST Version 1.1

DOR was defined as the time from first CR or PR whichever comes first until the time of disease progression by RECIST v1.1 or death due to any cause. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Disease progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

Time frame:
Time from first CR or PR until the time of disease progression or death due to any cause (up to 15 months)
Reported as:
Median · months
Duration of Objective Response (DOR), Evaluated Using RECIST Version 1.1
monthsX4P-001 Plus Nivolumab
Duration of Objective Response (DOR), Evaluated Using RECIST Version 1.1NA (NA to NA)
SecondaryTime to Objective Response, Evaluated Using RECIST Version 1.1

Time to objective response was defined as time from first administration of combination regimen to first CR or PR whichever comes first. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From administration of first dose of study medication (Day 1) until first appearance of CR or PR (up to 15 months)
Reported as:
Median · months
Time to Objective Response, Evaluated Using RECIST Version 1.1
monthsX4P-001 Plus Nivolumab
Time to Objective Response, Evaluated Using RECIST Version 1.1NA (NA to NA)
SecondaryDisease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.1

Disease control rate was defined as percentage of participants with best overall response of CR or PR or SD. CR: Disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) with a reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication (Day 1) until disease progression, study completion or early termination (up to 15 months)
Reported as:
Number · percentage of participants
Disease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.1
percentage of participantsX4P-001 Plus Nivolumab
Disease Control Rate: Percentage of Participants With CR or PR or Stable Disease (SD), Evaluated Using RECIST Version 1.188.9 (51.8 to 99.7)
SecondaryProgression Free Survival (PFS), Evaluated Using RECIST Version 1.1

PFS was defined as the time from first administration of study medication until objective tumor progression or death from any cause. Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. An unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication (Day 1) until disease progression or death from any cause (up to 15 months)
Reported as:
Median · months
Progression Free Survival (PFS), Evaluated Using RECIST Version 1.1
monthsX4P-001 Plus Nivolumab
Progression Free Survival (PFS), Evaluated Using RECIST Version 1.1NA (NA to NA)
SecondaryTime to Progression (TTP), Evaluated Using RECIST Version 1.1

TTP was defined as the time from first administration of study medication until objective tumor progression. Tumor progression: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study In addition to the relative increase of 20%, the sum also demonstrated an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions or the appearance of 1 or more new lesions was also considered progression.

Time frame:
From administration of first dose of study medication (Day 1) until disease progression (up to 15 months)
Reported as:
Median · months
Time to Progression (TTP), Evaluated Using RECIST Version 1.1
monthsX4P-001 Plus Nivolumab
Time to Progression (TTP), Evaluated Using RECIST Version 1.1NA (NA to NA)

Adverse events

Collected over From administration of first dose of study medication (Day 1) up to 30 days after last dose (up to 16 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
X4P-001 Plus Nivolumab0/9 (0%)2/9 (22.2%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventX4P-001 Plus Nivolumab
Alanine aminotransferase increasedInvestigations1/9
Aspartate aminotransferase increasedInvestigations1/9
Mucosal inflammationGeneral disorders1/9
Autoimmune hepatitisHepatobiliary disorders1/9
Rash maculo-papularSkin and subcutaneous tissue disorders1/9
EmbolismVascular disorders1/9
Most frequent other events
Showing 10 of 69
Most frequent other events
EventX4P-001 Plus Nivolumab
DiarrhoeaGastrointestinal disorders6/9
Nasal congestionRespiratory, thoracic and mediastinal disorders5/9
Dry eyeEye disorders4/9
CoughRespiratory, thoracic and mediastinal disorders4/9
FatigueGeneral disorders4/9
HeadacheNervous system disorders4/9
NauseaGastrointestinal disorders3/9
Weight decreasedInvestigations3/9
PruritusSkin and subcutaneous tissue disorders3/9
ArthralgiaMusculoskeletal and connective tissue disorders3/9

Baseline characteristics

Safety population included all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)X4P-001 Plus Nivolumab
Mean62.7 ± 8.85
Sex: Female, Male
Sex: Female, Male(Participants)X4P-001 Plus Nivolumab
Female1
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)X4P-001 Plus Nivolumab
Hispanic or Latino0
Not Hispanic or Latino8
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)X4P-001 Plus Nivolumab
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
08

Study locations

4 sites
  • Washington, District of Columbia, United States
  • Boston, Massachusetts, United States
  • Hackensack, New Jersey, United States
  • Chapel Hill, North Carolina, United States
09

References and documents

Publications

  • Choueiri TK, Atkins MB, Rose TL, Alter RS, Ju Y, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L, McDermott DF. A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Invest New Drugs. 2021 Aug;39(4):1019-1027. doi: 10.1007/s10637-020-01058-2. Epub 2021 Jan 28. PubMed 33507454 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Aug 2018, 20 months.

Results were first posted in Dec 2022, 4 years 4 months after primary completion. A results delay was requested in Jul 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2016
First posted
Oct 4, 2016
StartActual
Dec 7, 2016
Primary completionActual
Aug 8, 2018
CompletionActual
Aug 8, 2018
Results delay requested
Jul 24, 2019
Results first posted
Dec 29, 2022
Last update
Dec 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02923531
Lead sponsor
X4 Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 4, 2016
Start date
Dec 7, 2016
Primary completion
Aug 8, 2018
Completion
Aug 8, 2018
Results posted
Dec 29, 2022
Last update
Dec 29, 2022

Study contacts

Chief Medical Officer
study director · X4 Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mavorixafor

Start the discussion